CARISMA Therapeutics Inc CARM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CARM is a good fit for your portfolio.
News
-
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
-
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
Carisma Therapeutics to Present at Upcoming Conferences
-
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Carisma Therapeutics Announces Changes to its Board of Directors
-
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
-
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $1.64
- Day Range
- $1.60–1.70
- 52-Week Range
- $1.53–9.77
- Bid/Ask
- $1.66 / $1.70
- Market Cap
- $68.13 Mil
- Volume/Avg
- 506 / 170,376
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.69
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 107
- Website
- https://www.carismatx.com
Comparables
Valuation
|
Metric
|
CARM
|
VOR
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.51 | 0.76 | 2.91 |
Price/Sales | 3.69 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CARM
|
VOR
|
CELC
|
|---|---|---|---|
Quick Ratio | 4.88 | 8.81 | 12.78 |
Current Ratio | 5.06 | 9.04 | 13.43 |
Interest Coverage | — | — | −12.43 |
Quick Ratio
CARM
VOR
CELC
Profitability
|
Metric
|
CARM
|
VOR
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −75.96% | −41.83% | −35.57% |
Return on Equity (Normalized) | −618.03% | −51.69% | −49.08% |
Return on Invested Capital (Normalized) | −310.22% | −47.03% | −39.21% |
Return on Assets
CARM
VOR
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wcxcddqlzy | Twtl | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qfgvpzj | Nzcszdt | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dydpmbpj | Hzkbp | $97.8 Bil | |
MRNA
| Moderna Inc | Dzlbcyns | Nqwt | $41.3 Bil | |
ARGX
| argenx SE ADR | Lpvkkdqth | Cymg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cbwcsnhv | Smd | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qqxbrkndm | Lzxjpdj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qmsvpjfz | Jvvmdf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fcqwcvbfvp | Xbxfwd | $12.5 Bil | |
INCY
| Incyte Corp | Nxfsglwgx | Dxbznd | $11.6 Bil |